Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oyster Point Pharma, Inc. - common stock (NQ: OYST )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 11.06 (41)
Ask (Size) 11.17 (20)
Prev. Close 11.17
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 26,014,621
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7
Goldman Sachs' Hedge Fund Trend Monitor highlights concentration in mega-caps, with optimism in AI and health care. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
The 7 Best Crypto and Stocks to Buy as Christmas Gifts This Year
These stocks to buy as Christmas gifts provide a number of reasons for investors to rejoice this holiday season. 
Via InvestorPlace

Performance

More News

Read More
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
Via InvestorPlace
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
From Kahn Swick & Foti, LLC
Via Business Wire
Why Viatris Stock Is Jumping Today
Via The Motley Fool
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Better Dividend Stock: AbbVie or Viatris?
Via The Motley Fool
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From Oyster Point Pharma, Inc.
Via GlobeNewswire
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
From Brodsky & Smith LLC
Via GlobeNewswire
Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25%
Via Benzinga
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Via Benzinga
Dow Surges 400 Points; Crude Oil Down 1%
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Analyzing Oyster Point Pharma's Short Interest
Via Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Dow Jumps Over 200 Points; Verve Therapeutics Shares Plummet
Via Benzinga
Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share
Via Spotlight Growth
Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge
Via Benzinga
Viatris (VTRS) Stock Pops 17% on Acquisition News
Via InvestorPlace
US Stocks Mixed; Dow Rises Over 50 Points
Via Benzinga
OYST Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Oyster Point Pharma, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.